"Dec. 11, 2012 -- The diabetes and obesity epidemics may be fueling a dramatic rise in the number of people with vision problems, a new study suggests.
Rates of vision problems that can't be treated with glasses or contact lenses, know"...
NOT FOR INJECTION - FOR TOPICAL OPHTHALMIC USE ONLY
Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.
Fluress® (Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP) should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity is unknown; prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, systemic toxicity (manifested by central nervous system stimulation followed by depression) may occur.
Protection of the eye from irritating chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off.
Pregnancy Category C. Animal reproduction studies have not been conducted with Fluress® (fluorescein and benoxinate) . It is also not known whether Fluress® (fluorescein and benoxinate) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Fluress® (fluorescein and benoxinate) should be given to a pregnant woman only if clearly needed.
Caution should be exercised when Fluress® (fluorescein and benoxinate) is administered to a nursing woman.
The safety and effectiveness of this product in pediatric patients has not been established.
Last reviewed on RxList: 2/25/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Fluress Information
Report Problems to the Food and Drug Administration
Get breaking medical news.